Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sabatolimab + azacitidine + venetoclax in high/very high risk MDS
NCT04812548Phase 2Terminated
- Sponsor
- Novartis
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of sabatolimab in myelodysplastic syndrome (MDS), sponsored by Novartis. Started May 2021; status: terminated.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04812548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04812548.